14 August 2013 | Analysis | By BioSpectrum Bureau
Kang Li Da has so far been active in pre-marketing activities and in the regulatory process to get CFDA approval.
Singapore: Swedish medical technology company RaySearch Laboratories that develops advanced software solutions for improved radiation therapy of cancer has received China FDA (CFDA) approval for RaySearch's treatment planning system RayStation to be sold in Chinese market.
Since November 2011, RaySearch is represented on the Chinese market by the distributor Kang Li Da Trading Corporation, based in Beijing. Kang Li Da has so far been active in pre-marketing activities and in the regulatory process to get CFDA approval. Now when market approval has been secured Kang Li Da will be fully responsible for marketing, sales and service for RayStation on the entire Chinese market.
"China is the fastest growing radiation therapy market so this approval is of great strategic importance to us. Together with Kang Li Da we have already been active on the Chinese market for more than a year and a half so we know there is a large interest for RayStation in China. We are therefore very excited that we can now start offering RayStation to the Chinese clinics", says Mr. Johan LÃ¶f, CEO, RaySearch.